Second-Line Therapy in Extranodal Marginal Zone Lymphoma - Episode 5
Ariela Noy, MD:After a patient with disseminated disease has a relapse and the decision is made to retreat that patient, the physician has multiple options. Depending on the duration of the first remission, retreatment with rituximab may be a reasonable option, especially if the patient had a long disease-free interval and/or the patient is frail and other therapies may be too toxic. Patients who have a disease-free interval of under 1 year essentially should not be retreated with rituximab. Those patients are not likely to have a second response. If they do, it’s unlikely that it would be maintained.
The considerations for second-line therapy are similar but differ somewhat from the considerations in the first-line setting. The physician has many things to choose from, in terms of second-line therapy with chemoimmunotherapy. The patient could receive rituximab/bendamustine, R-CVP, R-CHOP, or, possibly, fludarabine-based therapy.
As of 2017, ibrutinib is also an FDA-approved option. Ibrutinib is a continuous oral therapy. Unlike chemotherapy, it has a better side effect profile. The treatment benefits about 88% of patients if one takes into consideration complete responses, partial responses, and disease shrinkage. The vast majority of patients will not have a complete response, however, with ibrutinib therapy. Currently, they maintain treatment with once-a-day oral dosing until they have disease progression or an adverse event that requires them to come off the drug or they simply don’t want to take pills any more.
Transcript edited for clarity.
A 64-Year-Old Woman With Advanced Extranodal MZL